YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
NASDAQ sign at times square at night by Lucky-photographer via iStock The S&P 500 Index ($SPX) (SPY) closed up by +1.49% on Monday, the Dow Jones Industrial Average ($DOWI) (DIA) closed up by +0.71%, and the Nasdaq 100 Index ($IUXX) (QQQ)…
The S&P 500 Index ($SPX) (SPY) is up by +0.93% today, the Dow Jones Industrial Average ($DOWI) (DIA) is up by +0.39%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +1.97%. December E-mini S&P futures (ESZ26) are up +1.00%, and December E-mi…
The S&P 500 Index ($SPX) (SPY) is up by +0.61% today, the Dow Jones Industrial Average ($DOWI) (DIA) is up by +0.17%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +1.33%. December E-mini S&P futures (ESZ26) are up +0.70%, and December E-mi…
For Immediate Release Chicago, IL – September 16 2026 – Zacks.com announces the list of stocks and ETFs featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the…
September marks Prostate Cancer Awareness Month, putting renewed attention on one of the most common cancer manifestations affecting men. The American Cancer Society estimates that 333,830 men in the United States will be diagnosed with pr…
By Mike Sheikh Cocrystal Pharma (NASDAQ: COCP) may look like another undercapitalized, clinical-stage biotech searching for its niche, and in need of a rescue, but there is more to this story than what meets the eye. Investors glancing at…
The oncolytic virus cancer therapy market is poised for significant growth, driven by increasing research and development of genetically engineered viruses that selectively target and destroy cancer cells while stimulating anti-tumor immun…
The non-metastatic prostate cancer market is expected to witness significant growth, driven by increasing disease awareness, improved screening practices, and advances in early-stage diagnosis. Additionally, a growing pipeline of therapies…
* Candel Therapeutics press release [https://seekingalpha.com/pr/20618191-candel-therapeutics-reports-second-quarter-2026-financial-results-and-recent-corporate] (CADL [https://seekingalpha.com/symbol/CADL]): Q2 GAAP EPS of -$0.52 misses b…
NEEDHAM, Mass., July 08, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for…
Candel Therapeutics NEEDHAM, Mass., July 08, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve…
(RTTNews) - "To be a successful business owner and investor, you have to be emotionally neutral to winning and losing. Winning and losing are just part of the game," said Robert Kiyosaki, American entrepreneur, investor, and author of Rich…
By Karen Roman Candel Therapeutics, Inc. (Nasdaq: CADL) said it appointed Mark Sims as Chief Commercial Officer effective July 6, 2026, having previously served at AstraZeneca as Vice President and Global Franchise Head, where he directed…
NEEDHAM, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for…
* Candel Therapeutics press release [https://seekingalpha.com/pr/20515327-candel-therapeutics-reports-first-quarter-2026-financial-results-and-recent-corporate] (CADL [https://seekingalpha.com/symbol/CADL]): Q1 GAAP EPS of -$0.14 beats by…
EVERSANA, a purpose-built, partner-led commercial organization, positions Candel for potential U.S. commercial launch following planned BLA submission in Q4 2026 NEEDHAM, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc.…
Extended long-term survival observed after an additional year of follow-up in ongoing phase 2a clinical trial, with 50% of 46 patients with advanced non-small cell lung cancer (NSCLC) treated with aglatimagene besadenovec (aglatimagene or…
* Candel Therapeutics press release [https://seekingalpha.com/pr/20434729-candel-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent] (CADL [https://seekingalpha.com/symbol/CADL]): Q4 GAAP EPS of -$0.54. * C…
Candel Therapeutics strengthens balance sheet as lead cancer therapy advances Proactive uses images sourced from Shutterstock Candel Therapeutics Inc (NASDAQ:CADL) is advancing plans to bring its lead cancer immunotherapy toward potential…
Company plans to initiate a pivotal phase 3 clinical trial of aglatimagene besadenovec (aglatimagene or CAN-2409) in patients with progressive, metastatic, non-squamous, non-small cell lung cancer (NSCLC) despite immune checkpoint inhibito…
Candel Therapeutics prices $100M public offering Proactive uses images sourced from Shutterstock Candel Therapeutics Inc (NASDAQ:CADL) told investors on Thursday it has priced its previously disclosed public offering of about 18.3 million…
(RTTNews) - Candel Therapeutics, Inc. (CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies, announced the pricing of 18.35 million common shares at $5.45 per share, expecting to rai…
NEEDHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fig…
* Candel Therapeutics (CADL [https://seekingalpha.com/symbol/CADL]) announced [https://seekingalpha.com/pr/20406758-candel-therapeutics-announces-proposed-100-million-public-offering] an underwritten public offering of $100M of its common…
Candel Therapeutics inks $100M funding agreement with RTW Investments, launches $100M public offering Proactive uses images sourced from Shutterstock Candel Therapeutics Inc (NASDAQ:CADL) on Thursday announced two financing initiatives to…
Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today: Darling Ingredients DAR is a provider of rendering, cooking oil and bakery waste recycling and recovery solutions. The Zacks Consensus Estimate for its current year…
NEEDHAM, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fig…
[Prostate cancer with organs and tumor or cancerous cells 3D rendering illustration. Anatomy, oncology, biomedical, disease, medical, biology, science, healthcare concepts.] libre de droit/iStock via Getty Images * Candel Therapeutics (CAD…
Presented new subgroup analyses from phase 3 clinical trial of CAN-2409 in localized prostate cancer at the American Society for Radiation Oncology (ASTRO) 2025 meeting, demonstrating improved prostate cancer-specific disease-free survival…
NEEDHAM, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fig…
NEEDHAM, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fig…
* Candel Therapeutics (NASDAQ:CADL [https://seekingalpha.com/symbol/CADL]) announced [https://seekingalpha.com/pr/20264571-candel-therapeutics-enters-into-130-million-term-loan-facility-with-trinity-capital-inc]on Tuesday that it has enter…
$50 million drawn down at closing, with access to up to an additional $80 millionStrengthens Company’s financial position; enables initiation of phase 3 clinical trial of CAN-2409 in non-small cell lung cancer (NSCLC)Provides non-dilutive…
NEEDHAM, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fig…
NEEDHAM, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fig…
CAN-2409 improved disease-free survival in patients with intermediate-to-high-risk, localized prostate cancer compared to placebo in patients treated with either conventional or moderate hypofractionated radiotherapy with curative intent,…